Roche (RHHBY) Stock Forecast & Price Target

$40.76

+1.20 (+3.03%)

(As of 07/26/2024 ET)

Stock Analysis Analyst Forecasts Chart Dividend Headlines Insider Trades Ownership Short Interest

Roche - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Roche in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 7 analysts, 2 have given a sell rating, and 5 have given a hold rating for RHHBY.

Consensus Price Target

$40.00
-1.86% Downside

High Forecast	$40.00
Average Forecast	$40.00
Low Forecast	$40.00

According to the 7 analysts' twelve-month price targets for Roche, the average price target is $40.00. The highest price target for RHHBY is $40.00, while the lowest price target for RHHBY is $40.00. The average price target represents a forecasted downside of -1.86% from the current price of $40.76.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Reduce	Reduce	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$40.00	$40.00	$40.00	$48.00
Forecasted Upside	-1.86% Downside	12.71% Upside	12.71% Upside	16.51% Upside

Get Roche Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Ad Darwin

Top Stock Unveiled!

Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

Get Your Free Report

RHHBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RHHBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Roche Stock vs. The Competition

Type	Roche	Medical Companies	S&P 500
Consensus Rating Score	1.71	2.72	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-1.86% Downside	3,123.40% Upside	9.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
5/30/2024	The Goldman Sachs Group 2 of 5 stars	Initiated Coverage	Sell
5/17/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars	Upgrade	Sell ➝ Hold
3/4/2024	Argus 2 of 5 stars	Reiterated Rating	Buy ➝ Hold
1/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight
9/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$45.00 ➝ $40.00	+12.71%
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/31/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
2/27/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
1/4/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underweight
12/14/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	CHF 328 ➝ CHF 329
11/15/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$48.00	+16.31%
9/15/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:44 AM ET.

RHHBY Forecast - Frequently Asked Questions

What is Roche's forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Roche is $40.00, with a high forecast of $40.00 and a low forecast of $40.00.
Should I buy or sell Roche stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche in the last twelve months. There are currently 2 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" RHHBY shares.
Does Roche's stock price have much upside?: According to analysts, Roche's stock has a predicted upside of 12.71% based on their 12-month stock forecasts.
Has Roche been upgraded by Wall Street analysts recently?: Over the previous 90 days, Roche's stock had 1 upgrade by analysts.
What analysts cover Roche?: Roche has been rated by research analysts at Deutsche Bank Aktiengesellschaft, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Roche more than its competitors?: Analysts like Roche less than other "medical" companies. The consensus rating for Roche is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RHHBY compares to other companies.